Curium is a leading global radiopharmaceutical company that develops, manufactures, and supplies radioactive tracers and nuclear medicines used to diagnose and treat cancer, heart, brain, and bone diseases, serving over 14 million patients across 70+ countries annually. The company also has a late-stage pipeline of Radioligand Therapies (RLTs) targeting neuroendocrine and prostate cancers, and is backed by CapVest Partners with a valuation of approximately $7 billion.
“Curium...agreed to buy Bedford, Mass.-based rival Lantheus for around $8b.”
Source→“Capvest Partners-backed Curium is in talks to acquire fellow radiopharmaceutical company Lantheus in a $7 billion take-private deal.”
Source→“Curium...is in talks to buy Bedford, Mass.-based radiopharma company Lantheus for around $7b”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.